Rezolute, Inc. (RZLT)
Chart Events
Performance Outlook
| Previous Close | 2.9300 |
| Open | 2.8700 |
| Bid | 0.5000 x 4000 |
| Ask | 4.5700 x 4000 |
| Day's Range | 2.8700 - 3.2889 |
| 52 Week Range | 2.2600 - 11.3100 |
| Volume | |
| Avg. Volume | 62,385 |
| Market Cap | 103.099M |
| Beta (5Y Monthly) | 2.85 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.0750 |
| Earnings Date | Sep 13, 2022 - Sep 19, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.75 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for RZLT
Related Research
- Rezolute, Inc.Daily – Vickers Top Buyers & Sellers for 05/19/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat3 months agoArgus Research
- GlobeNewswire
Rezolute Announces Promotion of Brian Roberts, M.D. to Chief Medical Officer
REDWOOD CITY, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today announced that Brian Roberts, M.D., previously Senior Vice President and Head of Clinical Development, has been promoted to Chief Medical Officer. Dr. Roberts joined Rezolute in 2017 as Vice President of Clinical Developm
- GlobeNewswire
Rezolute Reports Third Quarter Fiscal 2022 Financial Results and Highlights Company Progress
Announced a $130 million registered direct offering and concurrent private placement Positive topline results from Phase 2b RIZE study of RZ358 exceeded expectations and demonstrated highly significant reduction in hypoglycemia events, ~75% at anticipated therapeutic doses Positive data from Phase 1b multiple-ascending dose study of RZ402 enable Phase 2 proof-of-concept study initiation later this year REDWOOD CITY, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinic
- GlobeNewswire
Rezolute to Host Corporate Update Call on May 4, 2022
Company to Host Analyst and Investor Conference Call on Wednesday, May 4 at 4:30 p.m. ETREDWOOD CITY, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today announced that management will be hosting a corporate update call. The call will highlight recent pipeline advancements and continued
